- Home
- CELC vs BWMX Comparison
CELC vs BWMX Comparison
Compare CELC & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- BWMX
- Stock Information
- Founded
- CELC 2011
- BWMX 1995
- Country
- CELC United States
- BWMX Mexico
- Employees
- CELC N/A
- BWMX N/A
- Industry
- CELC Medical Specialities
- BWMX Catalog/Specialty Distribution
- Sector
- CELC Health Care
- BWMX Consumer Discretionary
- Exchange
- CELC Nasdaq
- BWMX Nasdaq
- Market Cap
- CELC 327.3M
- BWMX 360.5M
- IPO Year
- CELC 2017
- BWMX N/A
- Fundamental
- Price
- CELC $10.15
- BWMX $9.56
- Analyst Decision
- CELC Strong Buy
- BWMX Strong Buy
- Analyst Count
- CELC 6
- BWMX 1
- Target Price
- CELC $30.17
- BWMX $22.50
- AVG Volume (30 Days)
- CELC 190.9K
- BWMX 31.6K
- Earning Date
- CELC 05-14-2025
- BWMX 04-24-2025
- Dividend Yield
- CELC N/A
- BWMX 13.23%
- EPS Growth
- CELC N/A
- BWMX N/A
- EPS
- CELC N/A
- BWMX 0.74
- Revenue
- CELC N/A
- BWMX $684,841,453.00
- Revenue This Year
- CELC N/A
- BWMX $8.79
- Revenue Next Year
- CELC N/A
- BWMX $6.14
- P/E Ratio
- CELC N/A
- BWMX $12.60
- Revenue Growth
- CELC N/A
- BWMX 4.87
- 52 Week Low
- CELC $7.58
- BWMX $9.00
- 52 Week High
- CELC $19.77
- BWMX $18.38
- Technical
- Relative Strength Index (RSI)
- CELC 46.58
- BWMX 39.21
- Support Level
- CELC $9.64
- BWMX $9.20
- Resistance Level
- CELC $10.80
- BWMX $9.71
- Average True Range (ATR)
- CELC 0.66
- BWMX 0.59
- MACD
- CELC -0.06
- BWMX -0.02
- Stochastic Oscillator
- CELC 25.25
- BWMX 28.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.